Novartis AG ADR (NVS)vsP3 Health Partners Inc (PIII)
NVS
Novartis AG ADR
$142.71
+0.60%
HEALTHCARE · Cap: $271.25B
PIII
P3 Health Partners Inc
$7.05
-0.56%
HEALTHCARE · Cap: $1.61B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3672% more annual revenue ($56.69B vs $1.50B). NVS leads profitability with a 22.5% profit margin vs -6.5%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PIII
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$142.71
$49.31 premium
Intrinsic value data unavailable for PIII.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
No standout strengths identified
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : PIII
PIII has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PIII
The primary concerns for PIII are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.80 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while PIII is a turnaround play — different risk/reward profiles.
PIII carries more volatility with a beta of 1.62 — expect wider price swings.
PIII is growing revenue faster at 8.6% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 38/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →P3 Health Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
P3 Health Partners Inc (PIII) is a forward-thinking healthcare organization dedicated to enhancing care quality and minimizing costs through innovative, data-driven methodologies. Specializing in value-based care models, the company leverages telehealth technologies and advanced analytics to deliver tailored healthcare solutions, particularly targeting underserved populations. By collaborating with community organizations and maintaining a robust network of primary care providers and specialists, PIII addresses the growing demand for efficient healthcare services. With a steadfast commitment to high-quality, cost-effective care, PIII is well-positioned to thrive in the evolving healthcare environment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?